GlobeNewswire by notified

ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside


Houston, Texas, and Basel, Switzerland, November 2nd, 2023 – As Breast Cancer Awareness Month concludes, ARTIDIS announces the launch of its global multicenter clinical trial, ARTIDIS Nanomechanical Generated Measurements for Early Lesions (ANGEL - NCT06085833). Spearheaded by Dr. Alastair Thompson, Olga Keith Wiess chair of surgery and chief of the section of Breast Cancer Surgery at Baylor College of Medicine, this study aims to revolutionize breast cancer care using tissue nanomechanics to enhance diagnostics and optimize treatments. The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.

Drawing on a decade of impactful scientific research and literature [1-3], the ARTIDIS Nanomechanical Signature accurately gauges the mechanical properties of fresh tumor tissues to predict malignancy, aggressiveness, and treatment outcomes, while preserving tissue integrity for downstream measurements. Understanding nanomechanics is crucial as it determines cancer cell movement, intravasation, and the development of micro-metastases, often signifying aggressiveness. For instance, nanomechanical properties play a pivotal role in the metastasis process, where breast cancer cells can travel and grow in organs like the liver or lungs.

Integrated seamlessly into standard of care workflows, the ARTIDIS bedside device provides a rapid tool to identify malignant tissue and maintain tissue integrity for further assessments. Furthermore, the state-of-the-art ARTIDISNET combines clinical achievement data with the Nanomechanical Signature to offer a next-generation, integrated approach to personalized patient diagnostics and treatment. The innovative approach of the ARTIDIS Nanomechanical Phenotype platform has the potential to reshape first-line neoadjuvant therapy decisions by identifying malignant lesions capable of forming micro-metastases at the time of diagnosis.

The ANGEL study aims to validate the clinical utility of the Nanomechanical Signature by evaluating ARTIDIS' ability to assess bedside biopsies and accurately identify breast cancer subtypes as well as predict clinical outcomes and treatment response, especially in the realm of neoadjuvant therapy (NAT). Building on the NANO study at the University Hospital Basel, which confirmed the clinical value of the Nanomechanical Signature in distinguishing benign and malignant breast lesions in 545 patients, the ANGEL study strategically complements ARTIDIS recently established alliances to demonstrate novel treatment-optimization tools for patients with solid tumors in several distinct indications.

Dr. Alastair Thompson commented, “As a breast surgeon, I believe this study holds immense importance for breast cancer patients. Behind it is the understanding that physical properties of cancer cells contribute to their aggressiveness and response to treatment, a concept that could revolutionize our approach to diagnosis and treatment. Near patient testing in the clinic by the ARTIDIS machine will deliver results almost in real time and support both diagnostic and treatment decisions. This study has exceptional potential to improve patient experiences and revolutionize the standard of care in breast cancer. It is a privilege to be a part of it.”

The first recruitment sites for the global ANGEL study include Baylor St. Luke’s Medical Center and the Harris Health Smith Clinic in Houston, Texas, while the Claraspital in Basel, Switzerland will be the inaugural European center, with Dr. Rosanna Zanetti as the Lead Site Investigator. The study welcomes patients referred for biopsy or undergoing biopsy of a breast lesion following routine mammography, ultrasound, MRI, and/or clinical evaluation. All histological, imaging, treatment, and clinical outcome data will be integrated into the ARTIDISNET assessment. The study is estimated to complete enrollment within 24 months and includes a 10-year follow-up period.

Dr. Marija Plodinec, CEO of ARTIDIS, stated, "I am thrilled to have Dr. Thompson as the lead investigator in our groundbreaking clinical study. The ANGEL study specifically addresses the key challenges of personalized diagnosis and treatment decision-making, particularly in the field of neoadjuvant therapy. I am delighted that this clinical validation will enable us to deliver personalized diagnostics and treatment optimization to the patient bedside and help address and improve the entire patient journey.”

The ANGEL study is a significant step forward in realizing ARTIDIS’ vision of revolutionizing cancer care: it will provide patients with additional value without extra burden of cost or procedures and generate measurable patient-focused benefits such as reduced time-to-diagnosis, optimized and right-sized treatment choice and reduce side effects. Ensuring patients receive the best possible treatment from the start is crucial for improving outcomes for breast cancer patients.

Learn more about ANGEL (NCT06085833) study

[1] Plodinec, Loparic et al. Nature Nanotechnology, 2012 Nov;7(11):757-65. Link
[2] Burian et al. AACR Annual Meeting 2020, abstract LB-273. Link
[3] Nizzero et al. Annals of Oncology 2023, abstract 271P. Link


ARTIDIS is at the forefront of transforming cancer care, leading a mission to revolutionize treatment optimization across the entire patient journey, from central lab to patient bedside. By providing swift and precise diagnoses, along with predicting treatment responses from the very first biopsy, ARTIDIS is paving the way for a new era in cancer diagnostics. At the heart of their innovative medical technology lies a remarkable nanotechnology-based imaging modality, granting an unmatched and in-depth view of cancer at the cellular level. This groundbreaking technology centers around a unique Nanomechanical Signature - a tissue biomarker that accurately reflects the tissue phenotype. With a steadfast commitment to becoming the gold standard for tissue analysis and therapy optimization, this clinical stage company, headquartered in Basel, Switzerland, and with offices in Barcelona, Spain, and Houston, USA, aims to deliver substantial benefits to both patients and the healthcare system.

For more information contact:
Dr. Marija Plodinec, CEO
Phone: +41 61 633 29 95

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mandatory notification of trade and acceptance by primary insiders11.12.2023 17:12:12 CET | Press release

Reference is made to the stock exchange announcement on 7 December 2023 whereby BW Sirocco Holdings AS (the "Offeror") announced the completion and settlement of the Offer and the acquisition of the Offeror of 30,000,561 shares, representing approximately 95.21% of the total number of shares in BW Ideol AS. The Offeror, being a close associate of Marco Beenen, the chairperson of the board of directors of BW Ideol AS, attach the required notifications of trade to this announcement. Further, mandatory notifications from other primary insiders and their related parties are also attached to this announcement. For further information, please contact: BW Ideol AS Nicolas de Kerangal (Chief Financial & Partnerships Officer) +33 (0) 7 76 87 70 08 / ( BW Sirocco Holdings AS Anders S. Platou (Chief Strategy Officer BW Offshore Limited) +47 99 71 86 55 Attachment Project Sirocco - PDMR - Attachments

LambdaTest and Wipro Collaborate for Innovative Gen AI Solutions11.12.2023 17:00:00 CET | Press release

LambdaTest and Wipro forge a pioneering partnership, integrating Wipro’s Gen AI-powered QE capabilities with LambdaTest’s HyperExecute, to revolutionize software testing on the Cloud with advanced AI capabilities. San Francisco , Dec. 11, 2023 (GLOBE NEWSWIRE) -- LambdaTest, a leading cloud-based unified testing platform is partnering with Wipro Limited, a leading technology services and consulting company, to revolutionize software testing by integrating Wipro’s Gen AI powered QE platform IntelliAssure with HyperExecute - a continuous cloud test orchestration solution offered by Lambdatest. The partnership aims to provide organizations that are modernizing and migrating to the cloud with an easy-to-implement, plug-and-play solution for infusing analytics-driven intelligence across their testing lifecycle for improved productivity as well as hyper-accelerated release cycle times. LambdaTest and Wipro's collaborative integration promises cutting-edge capabilities with an aim to enrich t

Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub11.12.2023 16:30:00 CET | Press release

Press Release Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub Nokia Bell Labs is reaffirming its commitment to New Jersey, upholding its 80-year heritage of cutting-edge research and innovation in the state.Move will establish New Brunswick as Nokia’s new R&D hub on the East Coast and affirms Nokia’s commitment to this fast-growing innovation zone in the US. 11 December 2023 New Brunswick, New Jersey – Nokia today announced plans to relocate its campus in Murray Hill, NJ by 2028 to a new state-of-the-art research and development (R&D) facility in the burgeoning innovation and technology hub in New Brunswick, NJ. The new leading-edge R&D facility will propel Nokia Bell Labs to adapt and evolve to remain at the forefront of cutting-edge technology and continue contributing to a legacy of innovation in New Jersey. As the industrial research arm of Nokia, Nokia Bell Labs has always moved ahead of

Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties11.12.2023 16:30:00 CET | Press release

Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Anne Mette Toftegaard, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties. Please see attached report. Contact Please direct any questions regarding this announcement to: Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02 Attachment AS 26 2023 - Report on trading Anne Mette Toftegaard

Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations11.12.2023 16:30:00 CET | Press release

Press Release Nokia launches new venture partnerships and venture studio to maximize commercial potential of Nokia Bell Labs’ innovations Nokia Innovation Framework evolving with new venture studio and venture partnerships to unleash the full commercial potential of Nokia Bell Labs technologies outside of Nokia’s strategic perimeters. A new venture studio with America’s Frontier Fund and Roadrunner Venture Studios for commercializing the next generation of critical technology for the US will be situated in New Jersey, the iconic home of Bell Labs innovation for over 80 years.New venture partnership with Celesta Capital will invest in scaling ventures built with deep technologies from Nokia Bell Labs. 11 December 2023 Murray Hill, New Jersey – Nokia today announced an evolution to its Innovation Framework to unlock the full commercial potential of Nokia Bell Labs’ innovations across industries and expand efforts in external startup creation in the US with new partnerships and a new vent